The Medical Letter on Drugs and Therapeutics
Daclizumab (Zinbryta) for Multiple Sclerosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 3/6/18: Withdrawn from the market March 2018 due to safety concerns.

The FDA has approved daclizumab (Zinbryta – Biogen/Abbvie), an interleukin-2 (IL-2) receptor blocking monoclonal antibody, for treatment of adults with relapsing forms of multiple sclerosis (MS). It is the first subcutaneously injected monoclonal antibody to be approved for treatment of MS.

Because of safety concerns, the label recommends that daclizumab generally be used only for patients who have had an inadequate response to ≥2 other MS drugs, and its availability is restricted by a Risk Evaluation and Mitigation Strategy (REMS) program. Zenapax, an earlier IV formulation of daclizumab, was approved by the FDA in 1997 for prevention of acute renal transplant rejection,1 but it is no longer marketed.

TREATMENT OF MS — Interferons have been used for first-line treatment of MS, but they appear to be less effective than some of the newer drugs and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Daclizumab (Zinbryta) for Multiple Sclerosis
Article code: 1503b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian